

Special Issue on
**Multifunctional Gold Nanoparticles for Cancer
Theranostics**

CALL FOR PAPERS

Cancer is a severe threat to human health, with more than seven million deaths each year. Early detection and specific therapy have the potential to improve cancer patients' overall survival, but there are still unmet clinical needs of great significance. Nanotheranostics, a combination of diagnostics and therapeutics into one nanoprobe, has been attracting more and more interest in recent years, since it has the promise to perform image-guided therapy to improve treatment efficiency and specificity. In addition, theranostic nanoprobos can also improve cost-effectiveness, since multiple applications can be realized with only one product. Among different formulations, gold nanoparticles (nanorods, nanoshells, nanocages, nanostars, etc.) are especially promising due to their *in vivo* stability, biocompatibility, tunable surface plasmon resonance, and facile surface modification.

This special issue is aimed to publish high-quality research papers and review articles on the latest progress about multifunctional gold nanoparticles for cancer detection and treatment. Original studies that have not been published by other journals or conferences are welcome for submission. Papers discussing how gold nanoparticles can be translated into clinical studies will be particularly sought.

Potential topics include but are not limited to the following:

- ▶ Importance and significance of cancer nanotheranostics with plasmonic gold nanoparticles
- ▶ Comparison between active targeting and passive targeting with enhanced permeability and retention (EPR) effect
- ▶ Pharmacokinetics, biodistribution, and toxicity of gold nanoparticles with different size, shape, surface functionalization, and dose
- ▶ Sensitive cancer imaging and specific treatment with gold nanoparticles
- ▶ Bioclearable gold nanoparticles for cancer nanotheranostics

Authors can submit their manuscripts through the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/jnm/mnct/>.

Lead Guest Editor

Yang Liu, Duke University, Durham, USA
yl183@duke.edu

Guest Editors

Andrew Fales, Food and Drug Administration, Silver Spring, USA
andrew.fales@fda.hhs.gov

Junpeng Wang, Massachusetts Institute of Technology, Cambridge, USA
jwang267@mit.edu

Xiumei Ma, Shanghai Renji Hospital, Shanghai, China
sallyma@hotmail.com

Manuscript Due

Friday, 28 July 2017

First Round of Reviews

Friday, 20 October 2017

Publication Date

Friday, 15 December 2017